November 20, 2019

APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of 18F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults.

August 29, 2019

APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.

June 30, 2019

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been selected to join Johnson & Johnson Innovation’s JLABS and is now a resident company of JLABS @ Shanghai.

For more information, please click on “More” for the original press release from Johnson & Johnson Innovation.

May 22, 2019

APRINOIA Therapeutics announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.

March 25, 2019

APRINOIA was awarded as one of the top ten most innovative startups of Taiwan in 2019 by the Ministry of Science & Technology.

December 27, 2018

APRINOIA will be presenting the latest clinical trial results for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami, USA in January 2019. We will deliver a total of 10 presentations with our partners.

December 24, 2018

APRINOIA Therapeutics announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [18F]-labeled positron emission tomography (PET) imaging tracer, to support patient selection and efficacy evaluation in its global clinical trials.

October 11, 2018

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

August 31, 2018

APRINOIA will be sponsoring the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.

December 14, 2017

APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.

December 14, 2017

APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.

December 14, 2017

APRINOIA will be presenting the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.

December 14, 2017

APRINOIA will be presenting the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.

July 16, 2017

APRINOIA presented "Development of novel 3rd generation PBB3 tau PET tracer (APN-1701) and resulting collection of diverse structures with unique protein aggregate binding profiles" in July 2017.

December 11, 2016

APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.

December 11, 2016

APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.

December 04, 2016

APRINOIA is proud to host 2016 Taiwan Neuroscience Conference with Development Center for Biotechnology (DCB) and Academia Sinica on the 5th December 2016.

November 19, 2016

APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.